ArticleThe MAK collection for occupational health and safety2025
Naphthalene: MAK Value Documentation, addendum - Translation of the German version from 2022.
Article in The MAK collection for occupational health and safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The German Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area (MAK Commission) has summarized and re-evaluated the data for naphthalene [91-20-3] considering all toxicological end points. Relevant studies were identified from a literature search. The critical effects are the carcinogenic effects in rodents. No data in humans are available for these effects. In carcinogenicity studies, inhalation of naphthalene was found to cause neuroblastomas and adenomas in the noses of rats as well as bronchioloalveolar adenomas and carcinomas in mice. Naphthalene is not mutagenic in vitro, but robust data in vivo are not available. In general, DNA damage is induced in vitro and in vivo mostly at toxic doses. Mechanistic studies suggest that the carcinogenic potential arises from a non-genotoxic mechanism of action. This mechanism is initiated only at high concentrations by severe local inflammation leading to increased cell proliferation. However, a number of uncertainties remain. Thus, at present, a primary genotoxic mechanism of action cannot be ruled out completely for naphthalene. There are no studies from which an effect threshold in humans can be derived. Naphthalene thus remains classified in Carcinogen Category 2. As data for the accessibility of the germ cells are not available, naphthalene remains classified in Germ Cell Mutagen Category 3 B. No sensitizing potential can be derived from the available data. Naphthalene can be absorbed via the skin in toxicologically relevant amounts and remains designated with an "H".
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.